Enteritis – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Enteritis – Drugs In Development, 2024 report and make more profitable business decisions.
Enteritis is an inflammation of the intestines. It could be either infectious and non-infectious caused by bacteria, viral and protozoans. Secondary infections are caused by radiation, excess alcohol, drug toxicity. Mode of infection is air borne, inhalational, contaminated food, water. Etiology includes primarily pathogens and food poisoning too. Symptoms are primarily diarrhea, dehydration, weight loss, abdominal pain. Diagnosis is through physical examination and laboratory examination. Fecal examination to detect the pathogens causing the infection, CT scan of abdomen to evaluate complications associated and CBP, electrolytes to treat dehydration. Rehydration and antibiotics, antidiarrheals are the primary line of treatments then symptomatic therapy to treat fever, abdominal pain.
The Enteritis drugs in development market research report provide comprehensive information on the therapeutics under development for Enteritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Enteritis and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Enteritis | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 13 molecules, with 12 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Enteritis therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Enteritis pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Enteritis treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Acorda Therapeutics IncBeijing Scitech-MQ Pharmaceuticals Ltd
BioCurity Pharmaceuticals Inc
GNT Pharma Co Ltd
Innovent Biologics Inc
Liveome Co Ltd
Longwood Biopharmaceuticals Co Ltd
MetiMedi Pharmaceuticals Co Ltd
NovaCell Technology Inc
Theriva Biologics Inc
University of California Los Angeles
Xilingyuan Pharmaceutical Co Ltd
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Enteritis reports